Cyclooxygenase 2 Inhibitors

"Cyclooxygenase 2 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2.

Descriptor ID	D052246
MeSH Number(s)	D27.505.519.389.310.500 D27.505.696.663.850.014.040.500.500.500 D27.505.954.158.030.500.500 D27.505.954.329.030.500.500
Concept/Terms	Cyclooxygenase 2 Inhibitors Cyclooxygenase 2 Inhibitors Inhibitors, Cyclooxygenase 2 Cyclooxygenase-2 Inhibitors Inhibitors, Cyclooxygenase-2 Coxibs COX-2 Inhibitors COX 2 Inhibitors Inhibitors, COX-2 COX2 Inhibitors Inhibitors, COX2

Below are MeSH descriptors whose meaning is more general than "Cyclooxygenase 2 Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Cyclooxygenase Inhibitors [D27.505.519.389.310]
Cyclooxygenase 2 Inhibitors [D27.505.519.389.310.500]
Physiological Effects of Drugs [D27.505.696]
Peripheral Nervous System Agents [D27.505.696.663]
Sensory System Agents [D27.505.696.663.850]
Analgesics [D27.505.696.663.850.014]
Analgesics, Non-Narcotic [D27.505.696.663.850.014.040]
Anti-Inflammatory Agents, Non-Steroidal [D27.505.696.663.850.014.040.500]
Cyclooxygenase Inhibitors [D27.505.696.663.850.014.040.500.500]
Cyclooxygenase 2 Inhibitors [D27.505.696.663.850.014.040.500.500.500]
Therapeutic Uses [D27.505.954]
Anti-Inflammatory Agents [D27.505.954.158]
Anti-Inflammatory Agents, Non-Steroidal [D27.505.954.158.030]
Cyclooxygenase Inhibitors [D27.505.954.158.030.500]
Cyclooxygenase 2 Inhibitors [D27.505.954.158.030.500.500]
Antirheumatic Agents [D27.505.954.329]
Anti-Inflammatory Agents, Non-Steroidal [D27.505.954.329.030]
Cyclooxygenase Inhibitors [D27.505.954.329.030.500]
Cyclooxygenase 2 Inhibitors [D27.505.954.329.030.500.500]

Below are MeSH descriptors whose meaning is related to "Cyclooxygenase 2 Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Cyclooxygenase 2 Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cyclooxygenase 2 Inhibitors" by people in this website by year, and whether "Cyclooxygenase 2 Inhibitors" was a major or minor topic of these publications.

Bar chart showing 37 publications over 17 distinct years, with a maximum of 6 publications in 2007

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	0	1	1
2001	0	1	1
2003	0	5	5
2004	0	1	1
2005	0	2	2
2006	2	0	2
2007	5	1	6
2008	0	3	3
2009	3	1	4
2010	2	0	2
2011	2	1	3
2012	0	1	1
2013	0	1	1
2014	1	1	2
2021	1	0	1
2022	0	1	1
2024	0	1	1

Below are the most recent publications written about "Cyclooxygenase 2 Inhibitors" by people in Profiles.

Simmons R, Kameyama H, Kubota S, Sun Y, Langenheim JF, Ajeeb R, Shao TS, Ricketts S, Annan AC, Stratemeier N, Williams SJ, Clegg JR, Fung KM, Chervoneva I, Rui H, Tanaka T. Sustained delivery of celecoxib from nanoparticles embedded in hydrogel injected into the biopsy cavity to prevent biopsy-induced breast cancer metastasis. Breast Cancer Res Treat. 2024 Nov; 208(1):165-177.

View in: PubMed
Haffar A, Fillingham YA, Breckenridge L, Gursay D, Lonner JH. Meloxicam versus Celecoxib for Postoperative Analgesia after Total Knee Arthroplasty: Safety, Efficacy and Cost. J Am Acad Orthop Surg Glob Res Rev. 2022 04 05; 6(4).

View in: PubMed
Meyerhardt JA, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Bendell JC, Kumar P, Lewis D, Tan B, Bertagnolli M, Grothey A, Hochster HS, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. JAMA. 2021 04 06; 325(13):1277-1286.

View in: PubMed
Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015 Jan; 107(1):345.

View in: PubMed
Sawan H, Chen AF, Viscusi ER, Parvizi J, Hozack WJ. Pregabalin reduces opioid consumption and improves outcome in chronic pain patients undergoing total knee arthroplasty. Phys Sportsmed. 2014 May; 42(2):10-8.

View in: PubMed
Doll CM, Winter K, Gaffney DK, Ryu JK, Jhingran A, Dicker AP, Weidhaas JB, Miller BE, Magliocco AM. COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128. Int J Gynecol Cancer. 2013 Jan; 23(1):176-83.

View in: PubMed
Predina JD, Judy B, Fridlender ZG, Aliperti LA, Madajewski B, Kapoor V, Cheng G, Quatromoni J, Okusanya O, Singhal S. A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation. Cancer Biol Ther. 2012 Jul; 13(9):745-55.

View in: PubMed
Djavan B, Eastham J, Gomella L, Tombal B, Taneja S, Dianat SS, Kazzazi A, Shore N, Abrahamsson PA, Cheetham P, Moul J, Lepor H, Crawford ED. Testosterone in prostate cancer: the Bethesda consensus. BJU Int. 2012 Aug; 110(3):344-52.

View in: PubMed
Wenner MM, Edwards DG, Ray CA, Rose WC, Gardner TJ, Stillabower M, Farquhar WB. Celecoxib does not alter cardiovascular and renal function during dietary salt loading. Clin Exp Pharmacol Physiol. 2011 Aug; 38(8):543-9.

View in: PubMed
Parvizi J, Miller AG, Gandhi K. Multimodal pain management after total joint arthroplasty. J Bone Joint Surg Am. 2011 Jun 01; 93(11):1075-84.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement